Edwards Lifesciences (EW)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$89.90+0.13%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · EW
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $90 EW trades at 32× p/e, in line with its 28× p/e peer median, and our $84 fair value agrees. We hold it with medium confidence: our number sits below the analyst range. Analysts target $95–$110. Note: our $84 fair value sits below the entire analyst range ($95–$110). Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $101.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $126.71 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $134.33 | — | — | Hist. CAGR | high |
| graham number | 12M | $34.26 | — | — | TTM | high |
| Mgmt guidance |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$95.00 – $110.00 (median $101.00) · 7 analysts · as of 2026-07-28
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 65% over what the business is worth with no growth; closing that gap needs roughly 8.0 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $2.66/sh owner earnings.
Looks more expensive than peers.
Around its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $84.10 |
| 28.3 |
| 2.98 |
| Mgmt |
| high |
| Peer EV/EBITDA | 12M | $22.98 | 6.2 | 3.08 | TTM | high |
| Peer P/FCF | 12M | $61.17 | 24.6 | 2.48 | TTM | high |
| Peer P/E | 12M | $58.54 | 18.7 | 3.13 | ntm analyst | high |
| Peer P/S | 12M | $33.19 | 2.9 | 11.27 | TTM | high |
| PEG | 12M | $202.31 | 70.1 | 2.89 | TTM | high |
| residual income | 12M | $24.22 | — | — | TTM | high |
| Own P/E history | 12M | $93.23 | 32.3 | 2.89 | TTM | high |
| triangulated | 12M | $82.63 | 28.3 | 2.92 | Triangulated | high |
| Mgmt guidance | 3Y | $128.28 | 28.3 | 4.54 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $93.03 | 24.6 | 3.77 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $47.24 | 18.7 | 2.52 | Analyst | medium |
| Peer P/S | 3Y | $31.34 | 2.9 | 10.65 | guidance | medium |
| PEG | 3Y | $172.84 | 70.1 | 2.47 | Analyst | medium |
| Own P/E history | 3Y | $79.65 | 32.3 | 2.47 | Analyst | medium |
| Mgmt guidance | 5Y | $169.99 | 28.3 | 6.01 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $123.03 | 24.6 | 4.99 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $38.12 | 18.7 | 2.04 | Analyst | high |
| Peer P/S | 5Y | $25.29 | 2.9 | 8.59 | guidance | high |
| PEG | 5Y | $139.47 | 70.1 | 1.99 | Analyst | high |
| Own P/E history | 5Y | $64.27 | 32.3 | 1.99 | Analyst | high |